Best Papers on Ovarian Cancer

References

• Cyclophosphamide plus cisplatin versus cyclophosphamide,doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 9(9):1668–1674, 1991.
   PubMed Web of Science ®Google Scholar
• Buller RE, Manetta A, Bloss JO, DiSaia PJ, Berman ML: Does intraperitoneal CA-125 reflect disease status? Gynecol Oncol 40(1):66–69, 1991.
   Google Scholar
• Egorin M, Jodrell D, Canetta R, Langenberg P, Goldbloom E, Burroughs J, Goodlow J, Tan S, Wiltshaw E: Tumor response & toxicity in ovarian cancer correlates with carboplatin (CBDCA) area under the curve (AUC). Houston, TX, May 15-18, Proc Am Soc Clin Oncol 10:184, 1991 (abstr 600).
   Google Scholar
• Kacinski BM, King BL, Chambers SK, Schwartz PE, Carter D: Expression of the NEU oncogene in benign, borderline and invasive ovarian neoplasms and carcinoma-derived cell lines. Orlando, FL, Feb 17-20, 22nd Annual Meeting of Society of Gynecologic Oncologists 1991, p 30.
   Google Scholar
• Kaye SB: High dose cisplatin (100 mg/m2) is more effective than low dose (50 mg/m2) in combination with cyclophosphamide (750 mg/m2) for the treatment of advanced ovarian cancer. International Gynecologic Society, Third Biennial Meeting, Sept 22-26, 1991, Cairns, Australia, p 170.
   Google Scholar
• Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Alamadrones L, Hoskins W: Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer. J Clin Oncol 9(6):978–982, 1991.
   PubMed Web of Science ®Google Scholar
• Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9(3):389–393, 1991.
   PubMed Web of Science ®Google Scholar
• Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Rubin S, Lewis JL Jr, Phillips M, Almadrones L, Hoskins W: Phase I study of taxol administered by the intraperitoneal route: a GOG trial. Houston, TX, May 15-18, Proc Am Soc Clin Oncol 10:185, 1991 (abstr 601).
   Google Scholar
• McGurie WP, Hoskins WJ, Brady MS, Homesley HD, Clarke-Pearson DL: A phase III trial of dose intense (DI) versus standard dose (DS) cisplatin (CDDP) and cytoxan (CTX) in advanced ovarian cancer (AOC). International Gynecologic Society, Third Biennial Meeting, Sept 22-26, 1991, Cairns, Australia, p 35.
   Google Scholar
• McKenzie RS, Alberts DS, Bishop MR, McCloskey T, Sosman JA, Dolan JR, Koch D, Fisher RI, Stiff PJ: Phase I trial of high dose cyclophosphamide (CY), mitoxantrone (MX), and carboplatin (CB) with autologous bone marrow transplantation (ABMT) in female malignancies: pharmacologic levels of mitoxantrone and high response rate in refractory ovarian cancer. Houston, TX, May 15-18, Proc Am Soc Clin Oncol 10:186, 1991 (abstr 605).
   Google Scholar
• Meerpohl HG, Sauerbrei W, Scheulen ME, Pfleiderer A: Advanced ovarian cancer: analysis of factors influencing resectability at initial surgery. Houston, TX, May 15-18, Proc Am Soc Clin Oncol 10:193, 1991 (abstr 635).
   Google Scholar
• O'Brien M, Wiltshaw E, Tan S, Fryatt I: Stage I epithelial ovarian cancer (EOC): selecting patients for an adjuvant trial of chemotherapy. Houston, TX, May 15-18, Proc Am Soc Clin Oncol 10:191, 1991 (abstr 625).
   Google Scholar
• Omura GA, Brady MF, Homesley HD, Yordan E, Major FL, Buchsbaum HJ, Park RC: Longterm follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9(7):1138–1150, 1991.
   PubMed Web of Science ®Google Scholar
• Oram D, Davies AP, Jacobs I: Multimodal screening for ovarian cancer in post-menopausal women. International Gynecologic Society, Third Biennial Meeting, Sept 22-26, 1991, Cairns, Australia, p 37.
   Google Scholar
• Ozols RF: Importance of dose intensity in the treatment of patients with advanced ovarian cancer. International Gynecologic Society, Third Biennial Meeting, Sept 22-26, 1991, Cairns, Australia, p 61.
   Google Scholar
• Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM: Primary surgical therapy of ovarian cancer: how much and when Gynecol Oncol 40(3): 195–200, 1991.
   Google Scholar
• Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB, Markman M, Reichman B, Almadrones L, Lewis JL Jr: Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 42(2):137–141, 1991.
   PubMed Web of Science ®Google Scholar
• Sutton GP, Bundy BN, Omura GA, Yordan EL, Beecham JB, Bonfiglio T: Stage III ovarian tumors of low malignant potential treated with cisplatin combination chemotherapy (a Gynecologic Oncology Group study). Gynecol Oncol 41(3):230–233, 1991.
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink WW, van den Burg MEL, van Oosterom AT, Neijt JP, Guastalla JC, George M, Dalesio O, Vermorken JB: Longterm treatment results of a study comparing carboplatin with cisplatin in combination chemotherapy against advanced ovarian cancer. Houston, TX, May 15-18, Proc Am Soc Clin Oncol 10:196, 1991 (abstr 647).
   Google Scholar
• Vergote IB, Vergote LN, Trope CG: Adjuvant treatment in early ovarian cancer. International Gynecologic Society, Third Biennial Meeting, Sept. 22-26, 1991, Cairns, Australia, p 46.
   Google Scholar